Figure 3. IL-13 induced GCM protects HAE from SARS-CoV-2 in vitro by decreasing the abundance of receptor-expressing cells.

(a) Proportion of common cell types in vehicle- and IL-13-treated (20ng/mL, 55 days) samples (no virus exposure) determined by single cell RNA-seq data. n=3, p-value shown for unpaired t test. (b) Dot plot showing the effect of IL-13 treatment (20ng/mL, 55 days) on viral entry factor expression in uninfected HAE. Size of the dot represents % of the cell expressing the gene and color scale shows the average expression level. n = 3 donors (c) Representative image of immunofluorescence confocal microscopy for DAPI (nuclei, blue), N-protein (virus, green), and MUC5AC (goblet cells, red, top) or acetylated alpha tubulin (ciliated cells, red, bottom).